EICHORCondition: Breast Cancer · Sponsor: Region Skane
Interested? Contact the study team ↓
T-REX is a randomized multicenter, non-inferiority trial. Aim: To evaluate whether regional radiotherapy may safely be omitted in clinically node negative breast cancer patients with one or two sentinel node macrometastases and an estrogen receptor positive, HER2-negative tumor. Leading to an improved quality of life and reduced side effects, without worsening recurrence free survival at five years. Intervention: Patients will be randomized to locoregional radiotherapy towards the breast/chestwall and regional lymph nodes vs. to a de-escalated radiotherapy. In the intervention arm no lymph node irradiation will be given. Radiotherapy is still given to the remaining breast after breast conserving surgery, but no radiotherapy is given after mastectomy. Sample size: 1350 patients Primary end-point: Recurrence free survival at five years. Gene expression analysis: For all patients gene expression analysis for the gene signatures ARTIC, POLAR and OncotypeDX will be performed and related to risk of recurrence and benefit of adjuvant radiotherapy.
This description comes directly from the study's public registry record.
Sara Alkner, Associate professor · +4646171000 · sara.alkner@med.lu.se
T-REX Clinical Trials Office · +4646171000 · T_Rex.onkologi@skane.se
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Primary unifocal or multifocal invasive breast cancer T1-T2. 2. Clinically N0. 3. Macrometastasis (\>2mm) in 1-2 lymph nodes at sentinel node biopsy. 4. Oral and written consent. 5. Age ≥ 18 years. 6. All resection margins are tumor free (no tumor on ink). 7. Primary tumor ER-positive, HER2-negative. Exclusion Criteria: 1. Regional or distant metastases outside the ipsilateral axilla. 2. Previous RT towards the planned target area, i.e. the ipsilateral chest/lymph nodes. 3. Neoadjuvant systemic therapy. 4. Axillary lymph node dissection or other previous axillary surgery on the affected side. 5. Prior history of invasive breast cancer. 6. Pregnancy. 7. Bilateral invasive breast cancer. 8. Contraindication for radiotherapy or systemic treatment. 9. Inability to absorb or understand the contents of the informed consent form; for example, through disability, inadequate language skills or dementia. 10. Other invasive cancer within 5 years prior to breast cancer diagnosis
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Helsinki University Hospital | Helsinki, Finland | Recruiting |
| Lahti Hospital | Lahti, Finland | Not Yet Recruiting |
| Turku University Hospital | Turku, Finland | Not Yet Recruiting |
| Ålesund | Ålesund, Norway | Recruiting |
| Bergen | Bergen, Norway | Recruiting |
| Bodø | Bodø, Norway | Not Yet Recruiting |
| Gjövik | Gjøvik, Norway | Recruiting |
| Kristiansand | Kristiansand, Norway | Recruiting |
| Oslo | Oslo, Norway | Recruiting |
| Stavanger | Stavanger, Norway | Recruiting |
| Tromsø | Tromsø, Norway | Recruiting |
| Trondheim | Trondheim, Norway | Recruiting |
+ 18 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05634889